PriceTargets.com logo

Adaptive Biotechnologies - ADPT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.33
  • Forecasted Upside: 3.38%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$22.57 As of 07/31/2026 05:00 PM ET
▼ -1.61 (-6.66%)

This chart shows the closing price for ADPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adaptive Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADPT

Analyst Price Target is $23.33
▲ +3.38% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $23.33, with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a 3.38% upside from the last price of $22.57.

This chart shows the closing price for ADPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Adaptive Biotechnologies. This rating has held steady since April 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/30/2026GuggenheimBoost TargetBuy ➝ Buy$22.00 ➝ $25.00
7/30/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $22.00
7/30/2026TD CowenBoost TargetBuy ➝ Buy$25.00 ➝ $28.00
7/30/2026BTIG ResearchBoost TargetBuy ➝ Buy$24.00 ➝ $25.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/15/2026TD CowenReiterated RatingBuy ➝ Buy
7/9/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$18.00 ➝ $20.00
6/29/2026GuggenheimBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
6/17/2026BTIG ResearchReiterated RatingBuy ➝ Buy$22.00
5/12/2026Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$21.00 ➝ $18.00
5/6/2026TD CowenBoost TargetBuy ➝ Buy$19.00 ➝ $21.00
5/6/2026JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$21.00 ➝ $19.00
5/6/2026GuggenheimReiterated RatingBuy ➝ Buy$21.00
5/6/2026BTIG ResearchReiterated RatingBuy ➝ Buy$22.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
2/6/2026TD CowenReiterated RatingBuy ➝ Buy
2/6/2026BTIG ResearchBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
2/6/2026Piper SandlerSet Target$21.00
2/6/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$20.00 ➝ $21.00
1/26/2026GuggenheimBoost TargetBuy ➝ Buy$20.00 ➝ $21.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/7/2026TD CowenReiterated RatingBuy ➝ Buy
12/1/2025Morgan StanleyInitiated CoverageEqual Weight$21.00
11/11/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$11.00 ➝ $16.00
11/6/2025BTIG ResearchBoost TargetBuy ➝ Buy$19.00 ➝ $21.00
11/6/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$17.00 ➝ $20.00
10/22/2025BTIG ResearchBoost TargetBuy ➝ Buy$14.00 ➝ $19.00
10/15/2025Piper SandlerBoost TargetOverweight ➝ Overweight$15.00 ➝ $20.00
10/13/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$14.00 ➝ $17.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025GuggenheimInitiated CoverageBuy$20.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/6/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$10.00 ➝ $14.00
8/6/2025TD CowenBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
8/6/2025Piper SandlerBoost TargetOverweight ➝ Overweight$13.00 ➝ $15.00
6/18/2025Craig HallumInitiated CoverageBuy$15.00
5/6/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.00
5/5/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.00
5/2/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
3/21/2025The Goldman Sachs GroupUpgradeNeutral ➝ Buy$8.00 ➝ $9.00
2/20/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$7.00 ➝ $11.00
2/13/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$10.00 ➝ $12.00
1/28/2025The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$5.50 ➝ $7.50
12/18/2024BTIG ResearchBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
11/11/2024Piper SandlerBoost TargetOverweight ➝ Overweight$6.00 ➝ $7.00
10/2/2024BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
8/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$5.00 ➝ $6.00
4/4/2024BTIG ResearchLower TargetBuy ➝ Buy$6.00 ➝ $5.00
2/16/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$11.00 ➝ $5.00
2/15/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$11.00 ➝ $8.00
11/13/2023Piper SandlerLower TargetOverweight ➝ Overweight$13.00 ➝ $6.00
11/10/2023William BlairReiterated RatingOutperform
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $10.00
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $13.00
8/8/2023Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $14.00
8/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
5/8/2023Piper SandlerBoost Target$14.00 ➝ $15.00
2/16/2023Morgan StanleyLower TargetEqual Weight$16.00 ➝ $15.00
2/15/2023Credit Suisse GroupReiterated RatingUnderperform$7.00
1/4/2023ScotiabankInitiated CoverageSector Outperform$15.00
12/21/2022Piper SandlerUpgradeNeutral ➝ Overweight$7.50 ➝ $14.00
11/7/2022Morgan StanleyLower TargetEqual Weight$17.00 ➝ $16.00
10/26/2022Piper SandlerLower TargetNeutral$12.00 ➝ $7.50
8/24/2022Credit Suisse GroupInitiated CoverageUnderperform$8.00
8/17/2022Piper SandlerBoost TargetNeutral$7.50 ➝ $12.00
8/9/2022BTIG ResearchLower Target$17.00
6/2/2022Piper SandlerInitiated CoverageNeutral$7.50
5/24/2022The Goldman Sachs GroupLower TargetNeutral$14.00 ➝ $10.00
2/16/2022Bank of AmericaLower TargetBuy$40.00 ➝ $32.00
2/16/2022JPMorgan Chase & Co.Lower TargetOverweight$75.00 ➝ $50.00
2/16/2022The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$54.00 ➝ $21.00
2/16/2022BTIG ResearchLower TargetBuy$35.00 ➝ $30.00
2/15/2022Morgan StanleyLower TargetEqual Weight$46.00 ➝ $27.00
1/11/2022BTIG ResearchLower Target$55.00 ➝ $45.00
10/15/2021William BlairReiterated RatingOutperform
10/15/2021TD CowenInitiated CoverageOutperform
8/6/2021The Goldman Sachs GroupLower TargetNeutral$59.00 ➝ $52.00
(Data available from 8/2/2021 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/4/2026
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 22 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/2/2026

Current Sentiment

  • 22 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $22.57
Low: $22.41
High: $24.57

50 Day Range

MA: $19.43
Low: $13.84
High: $24.18

52 Week Range

Now: $22.57
Low: $9.96
High: $24.57

Volume

2,992,828 shs

Average Volume

2,596,374 shs

Market Capitalization

$3.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Adaptive Biotechnologies?

The following sell-side analysts have issued reports on Adaptive Biotechnologies in the last twelve months: BTIG Research, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ADPT.

What is the current price target for Adaptive Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for Adaptive Biotechnologies in the last year. Their average twelve-month price target is $23.33, suggesting a possible upside of 3.4%. TD Cowen has the highest price target set, predicting ADPT will reach $28.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $19.00 for Adaptive Biotechnologies in the next year.
View the latest price targets for ADPT.

What is the current consensus analyst rating for Adaptive Biotechnologies?

Adaptive Biotechnologies currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ADPT.

What other companies compete with Adaptive Biotechnologies?

Other companies that are similar to Adaptive Biotechnologies include Elanco Animal Health, Axsome Therapeutics, Arrowhead Pharmaceuticals, Abivax and Summit Therapeutics. Learn More about companies similar to Adaptive Biotechnologies.

How do I contact Adaptive Biotechnologies' investor relations team?

Adaptive Biotechnologies' physical mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company's listed phone number is (206) 659-0067 and its investor relations email address is [email protected]. The official website for Adaptive Biotechnologies is www.constructionpartners.net. Learn More about contacing Adaptive Biotechnologies investor relations.